Not all psoriasis data tell the same story, and sometimes the loudest signal isn’t the most important one. In this episode of the JDD Podcast, host Dr. Adam Friedman sits down with internationally recognized psoriasis expert and clinical trial titan Dr. Andrew Blauvelt to unpack the critical nuances of clinical trial design, data interpretation, and how evidence can shape, or distort, clinical perception.
Before diving into any one therapy, Drs. Friedman and Blauvelt explore the foundations of data literacy, discussing how study design, endpoint selection, duration of follow-up, and safety reporting can dramatically influence how clinicians interpret efficacy and risk. They examine common pitfalls that lead to apples to oranges comparisons and discuss how early narratives can sometimes outpace the totality of evidence. Applying this framework to bimekizumab (Bimzelx), the conversation tackles persistent questions surrounding its safety profile, including the often-discussed candidiasis signal, while reviewing key lessons from the BE READY, BE VIVID, BE SURE, and BE RADIANT clinical programs. The discussion also highlights the growing importance of long-term disease control, including four year “no flare” data that may challenge traditional treatment expectations in psoriasis.
Whether you’re evaluating a new therapy, comparing clinical trials, or simply trying to separate signal from noise, this episode offers practical insights into translating data into confidence, and ultimately into better patient management. You’re welcome.
